New tool helps clinicians assess patients who develop COVID-19 symptoms

February 10, 2021

BOSTON - When patients arrive in emergency departments and hospitals with symptoms consistent with COVID-19, it's critical to isolate them to avoid the potential spread of infection, but keeping patients isolated longer than needed could delay patient care, take up hospital beds needed for other patients, and unnecessarily use up personal protective equipment. A team led by investigators at Massachusetts General Hospital (MGH) has now created a tool to guide frontline clinicians through diagnostic evaluations of such patients so that they'll know when it's safe to discontinue precautions. The tool was developed and validated in a study published in Clinical Infectious Diseases.

In the spring of 2020, due to the risk of false-negative test results, the Infectious Diseases Society of America recommended repeating a COVID-19 test in patients with moderate to high probability of COVID-19; however, there was little guidance about what factors led to a patient being low or high probability. "So a team of infectious disease specialists at MGH worked around the clock to review admitted patients one by one to provide guidance about who needed additional testing and whose probability of COVID-19 was low enough that isolation could be discontinued," says Caitlin Dugdale, MD, an infectious disease physician at MGH and one of the study's co-first authors.

The effort led to the creation of a tool called the COvid Risk cALculator (CORAL), a clinical-decision support system embedded within the electronic health record. It was developed based on a rigorous review of the medical literature and the experience of a team of infectious disease specialists.

When using CORAL for a patient with symptoms of COVID-19, a clinician answers several questions about the patient's risk factors, symptoms and imaging findings, and is guided through a standardized COVID-19 diagnostic workup of the patient based on up-to-date guidelines.

"We designed the CORAL tool to be easy for frontline clinicians to use and also to help ensure patient and health care personnel safety," says Erica Shenoy, MD, PhD, an infectious diseases physician and infection control expert and co-senior author of the study, who has served as the infection control clinical lead for Mass General Brigham's electronic health record for several years. "By standardizing the approach to the assessment of patients with symptoms of COVID-19, we minimize the chance that a patient with a false-negative test escapes detection, which could put other patients and health care personnel at risk of exposure."

In the study, CORAL dramatically reduced the time required by clinicians to assess patients, and it decreased the average time that hospitalized patients were kept in isolation during evaluation for COVID-19. Among 2,000 patients assessed with CORAL, none had a positive COVID-19 test within seven days after discontinuation of precautions via CORAL.

Since CORAL's launch in May 2020, it has been used more than 30,000 times and is now in place at eight acute care hospitals in the Boston area, as well as four rehabilitation hospitals. An outpatient version of CORAL was launched in October 2020 and is in use in hundreds of Mass General Brigham affiliated practices.

Importantly, CORAL can be rapidly adapted as new guidelines or research related to COVID-19 diagnostics emerge.
Emily Hyle, MD, one of the leaders of the Infectious Diseases review team at MGH, is co-senior author of the study. David Rubins, MD, an internist and informaticist, is co-first author of the study, and he co-leads the clinical decision support team for Mass General Brigham.

This work was supported by departmental funds and the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Centers for Disease Control and Prevention, Harvard Catalyst, the Cystic Fibrosis Foundation, the Sullivan Family Foundation and the Roger I. and Ruth B. MacFarlane Foundation.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Infection Articles from Brightsurf:

Halving the risk of infection following surgery
New analysis by the University of Leeds and the University of Bern of more than 14,000 operations has found that using alcoholic chlorhexidine gluconate (CHG) halves the risk of infection in certain types of surgery when compared to the more commonly used povidone-iodine (PVI).

How plants shut the door on infection
A new study by an international team including University of Maryland scientists has discovered the key calcium channel responsible for closing plant pores as an immune response to pathogen exposure.

Sensing infection, suppressing regeneration
UIC researchers describe an enzyme that blocks the ability of blood vessel cells to self-heal.

Boost to lung immunity following infection
The strength of the immune system in response to respiratory infections is constantly changing, depending on the history of previous, unrelated infections, according to new research from the Crick.

Is infection after surgery associated with increased long-term risk of infection, death?
Whether experiencing an infection within the first 30 days after surgery is associated with an increased risk of another infection and death within one year was the focus of this observational study that included about 660,000 veterans who underwent major surgery.

Revealed: How E. coli knows how to cause the worst possible infection
The discovery could one day let doctors prevent the infection by allowing E. coli to pass harmlessly through the body.

UK study shows most patients with suspected urinary tract infection and treated with antibiotics actually lack evidence of this infection
New research presented at this week's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Netherlands (April 13-16, 2019) shows that only one third of patients that enter the emergency department with suspected urinary tract infection (UTI) actually have evidence of this infection, yet almost all are treated with antibiotics, unnecessarily driving the emergence of antimicrobial resistance.

Bacteria in urine doesn't always indicate infection
Doctors should think carefully before testing patients for a urinary tract infection (UTI) to avoid over-diagnosis and unnecessary antibiotic treatment, according to updated asymptomatic bacteriuria (ASB) guidelines released by the Infectious Diseases Society of America (IDSA) and published in Clinical Infectious Diseases.

Subsidies for infection control to healthcare institutions help reduce infection levels
Researchers compared three types of infection control subsidies and found that under a limited budget, a dollar-for-dollar matching subsidy, in which policymakers match hospital spending for infection control measures, was the most effective at reducing the number of hospital-acquired infections.

Dengue virus infection may cause severe outcomes following Zika virus infection during pregnancy
This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.

Read More: Infection News and Infection Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to